Search results
Results from the WOW.Com Content Network
Patented Medicine Prices Review Board office in Ottawa. Bill C-22, which was passed in 1987, established a compulsory licensing system under which drug patent holders were required to allow competing drug manufacturers to import their patented drug in exchange for a very modest 4% royalty, which resulted in an increase in the market share of generic drugs.
In Canada, the medication pricing is overseen by the Patented Medicine Prices Review Board (PMPRB), which monitors the prices set for patented drugs. [62] One way the PMPRB evaluates whether drug pricing by patentees is excessive by considering international drug pricing. [63] The PMPRB also compares the price of the drug to a similar market. [64]
In Canada, the Patented Medicine Prices Review Board (PMPRB) determines a maximum price for all drugs. In 1987, Bill C-22 established an extended period of protection for patents prior to licensing, which would allow for generics to enter the market.
This page was last edited on 12 September 2024, at 23:12 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
For example, in the UK the Pharmaceutical Price Regulation Scheme is intended to ensure that the National Health Service is able to purchase drugs at "reasonable prices". In Canada, the Patented Medicine Prices Review Board examines drug pricing, compares the proposed Canadian price to that of seven other countries and determines if a price is ...
Patented Medicine Prices Review Board Public Health Agency of Canada As of 2023 [update] , the Health Portfolio consists of approximately 12,000 full-time equivalent employees and an annual budget of over $3.8 billion.
For premium support please call: 800-290-4726 more ways to reach us
the Patented Medicine Prices Review Board; and the Canadian Food Inspection Agency Additionally, Health Canada is a corporate partner of the Canadian Association of Emergency Physicians (CAEP).